nodes	percent_of_prediction	percent_of_DWPC	metapath
Indapamide—CA5B—cervicothoracic ganglion—systemic scleroderma	0.119	0.594	CbGeAlD
Indapamide—KCNE1—lung—systemic scleroderma	0.00997	0.0497	CbGeAlD
Indapamide—CA7—digestive system—systemic scleroderma	0.00602	0.03	CbGeAlD
Indapamide—KCNQ1—digestive system—systemic scleroderma	0.00548	0.0273	CbGeAlD
Indapamide—CA12—connective tissue—systemic scleroderma	0.00541	0.027	CbGeAlD
Indapamide—CA9—digestive system—systemic scleroderma	0.00528	0.0263	CbGeAlD
Indapamide—CA9—tendon—systemic scleroderma	0.00503	0.0251	CbGeAlD
Indapamide—SLC12A3—lung—systemic scleroderma	0.00492	0.0245	CbGeAlD
Indapamide—KCNQ1—lung—systemic scleroderma	0.00458	0.0228	CbGeAlD
Indapamide—CA12—digestive system—systemic scleroderma	0.00391	0.0195	CbGeAlD
Indapamide—CA5B—tendon—systemic scleroderma	0.00334	0.0166	CbGeAlD
Indapamide—CA12—lung—systemic scleroderma	0.00326	0.0163	CbGeAlD
Indapamide—CA5B—lung—systemic scleroderma	0.00293	0.0146	CbGeAlD
Indapamide—CA2—connective tissue—systemic scleroderma	0.00278	0.0138	CbGeAlD
Indapamide—CA2—smooth muscle tissue—systemic scleroderma	0.00254	0.0127	CbGeAlD
Indapamide—CA2—skin of body—systemic scleroderma	0.00251	0.0125	CbGeAlD
Indapamide—CA4—digestive system—systemic scleroderma	0.00242	0.0121	CbGeAlD
Indapamide—CA4—tendon—systemic scleroderma	0.0023	0.0115	CbGeAlD
Indapamide—CA4—lung—systemic scleroderma	0.00202	0.0101	CbGeAlD
Indapamide—CA2—digestive system—systemic scleroderma	0.00201	0.01	CbGeAlD
Indapamide—CA2—tendon—systemic scleroderma	0.00191	0.00951	CbGeAlD
Indapamide—CA2—lung—systemic scleroderma	0.00168	0.00835	CbGeAlD
Indapamide—CYP3A4—digestive system—systemic scleroderma	0.00129	0.00645	CbGeAlD
Indapamide—Erectile dysfunction—Prednisone—systemic scleroderma	0.00043	0.000538	CcSEcCtD
Indapamide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00043	0.000538	CcSEcCtD
Indapamide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000429	0.000536	CcSEcCtD
Indapamide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000429	0.000536	CcSEcCtD
Indapamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000428	0.000535	CcSEcCtD
Indapamide—Nausea—Mometasone—systemic scleroderma	0.000427	0.000534	CcSEcCtD
Indapamide—Anorexia—Lisinopril—systemic scleroderma	0.000426	0.000533	CcSEcCtD
Indapamide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000425	0.000532	CcSEcCtD
Indapamide—Ataxia—Methotrexate—systemic scleroderma	0.000425	0.000531	CcSEcCtD
Indapamide—Pain—Mycophenolic acid—systemic scleroderma	0.000424	0.000531	CcSEcCtD
Indapamide—Constipation—Mycophenolic acid—systemic scleroderma	0.000424	0.000531	CcSEcCtD
Indapamide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000424	0.000531	CcSEcCtD
Indapamide—Weight decreased—Prednisone—systemic scleroderma	0.000422	0.000529	CcSEcCtD
Indapamide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000422	0.000528	CcSEcCtD
Indapamide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000421	0.000527	CcSEcCtD
Indapamide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000419	0.000524	CcSEcCtD
Indapamide—Hypotension—Lisinopril—systemic scleroderma	0.000418	0.000523	CcSEcCtD
Indapamide—Dizziness—Captopril—systemic scleroderma	0.000417	0.000522	CcSEcCtD
Indapamide—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000417	0.000522	CcSEcCtD
Indapamide—Depression—Prednisone—systemic scleroderma	0.000415	0.000519	CcSEcCtD
Indapamide—Urticaria—Leflunomide—systemic scleroderma	0.000413	0.000517	CcSEcCtD
Indapamide—Abdominal pain—Leflunomide—systemic scleroderma	0.000411	0.000515	CcSEcCtD
Indapamide—Body temperature increased—Leflunomide—systemic scleroderma	0.000411	0.000515	CcSEcCtD
Indapamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000409	0.000512	CcSEcCtD
Indapamide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000409	0.000511	CcSEcCtD
Indapamide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000409	0.000511	CcSEcCtD
Indapamide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000409	0.000511	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000407	0.00051	CcSEcCtD
Indapamide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000407	0.000509	CcSEcCtD
Indapamide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000407	0.000509	CcSEcCtD
Indapamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000406	0.000508	CcSEcCtD
Indapamide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000406	0.000508	CcSEcCtD
Indapamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000406	0.000508	CcSEcCtD
Indapamide—Insomnia—Lisinopril—systemic scleroderma	0.000404	0.000506	CcSEcCtD
Indapamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000404	0.000505	CcSEcCtD
Indapamide—Paraesthesia—Lisinopril—systemic scleroderma	0.000401	0.000502	CcSEcCtD
Indapamide—Vomiting—Captopril—systemic scleroderma	0.000401	0.000502	CcSEcCtD
Indapamide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.0004	0.0005	CcSEcCtD
Indapamide—Dyspnoea—Lisinopril—systemic scleroderma	0.000399	0.000499	CcSEcCtD
Indapamide—Rash—Captopril—systemic scleroderma	0.000398	0.000498	CcSEcCtD
Indapamide—Dermatitis—Captopril—systemic scleroderma	0.000398	0.000498	CcSEcCtD
Indapamide—Somnolence—Lisinopril—systemic scleroderma	0.000397	0.000497	CcSEcCtD
Indapamide—Headache—Captopril—systemic scleroderma	0.000395	0.000495	CcSEcCtD
Indapamide—Dyspepsia—Lisinopril—systemic scleroderma	0.000394	0.000492	CcSEcCtD
Indapamide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000392	0.000491	CcSEcCtD
Indapamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000392	0.000491	CcSEcCtD
Indapamide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000392	0.00049	CcSEcCtD
Indapamide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000392	0.00049	CcSEcCtD
Indapamide—Asthma—Methotrexate—systemic scleroderma	0.00039	0.000488	CcSEcCtD
Indapamide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000389	0.000487	CcSEcCtD
Indapamide—Decreased appetite—Lisinopril—systemic scleroderma	0.000389	0.000486	CcSEcCtD
Indapamide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000386	0.000483	CcSEcCtD
Indapamide—Fatigue—Lisinopril—systemic scleroderma	0.000385	0.000482	CcSEcCtD
Indapamide—Shock—Mycophenolate mofetil—systemic scleroderma	0.000385	0.000482	CcSEcCtD
Indapamide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000384	0.000481	CcSEcCtD
Indapamide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000384	0.00048	CcSEcCtD
Indapamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000383	0.00048	CcSEcCtD
Indapamide—Pancreatitis—Methotrexate—systemic scleroderma	0.000383	0.000479	CcSEcCtD
Indapamide—Pain—Lisinopril—systemic scleroderma	0.000382	0.000478	CcSEcCtD
Indapamide—Constipation—Lisinopril—systemic scleroderma	0.000382	0.000478	CcSEcCtD
Indapamide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000382	0.000478	CcSEcCtD
Indapamide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00038	0.000476	CcSEcCtD
Indapamide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000379	0.000474	CcSEcCtD
Indapamide—Diarrhoea—Azathioprine—systemic scleroderma	0.000377	0.000472	CcSEcCtD
Indapamide—Nausea—Captopril—systemic scleroderma	0.000375	0.000469	CcSEcCtD
Indapamide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000373	0.000467	CcSEcCtD
Indapamide—Asthenia—Leflunomide—systemic scleroderma	0.000373	0.000467	CcSEcCtD
Indapamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000368	0.000461	CcSEcCtD
Indapamide—Pruritus—Leflunomide—systemic scleroderma	0.000368	0.000461	CcSEcCtD
Indapamide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000366	0.000458	CcSEcCtD
Indapamide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000366	0.000457	CcSEcCtD
Indapamide—Dysuria—Methotrexate—systemic scleroderma	0.000365	0.000457	CcSEcCtD
Indapamide—Dizziness—Azathioprine—systemic scleroderma	0.000364	0.000456	CcSEcCtD
Indapamide—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000359	0.00045	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000357	0.000447	CcSEcCtD
Indapamide—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000356	0.000446	CcSEcCtD
Indapamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000356	0.000446	CcSEcCtD
Indapamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000356	0.000445	CcSEcCtD
Indapamide—Urticaria—Lisinopril—systemic scleroderma	0.000355	0.000444	CcSEcCtD
Indapamide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000354	0.000443	CcSEcCtD
Indapamide—Abdominal pain—Lisinopril—systemic scleroderma	0.000353	0.000442	CcSEcCtD
Indapamide—Body temperature increased—Lisinopril—systemic scleroderma	0.000353	0.000442	CcSEcCtD
Indapamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000352	0.00044	CcSEcCtD
Indapamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000351	0.000439	CcSEcCtD
Indapamide—Vomiting—Azathioprine—systemic scleroderma	0.00035	0.000438	CcSEcCtD
Indapamide—Pneumonia—Methotrexate—systemic scleroderma	0.00035	0.000438	CcSEcCtD
Indapamide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000349	0.000437	CcSEcCtD
Indapamide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000348	0.000436	CcSEcCtD
Indapamide—Drowsiness—Methotrexate—systemic scleroderma	0.000348	0.000435	CcSEcCtD
Indapamide—Rash—Azathioprine—systemic scleroderma	0.000347	0.000435	CcSEcCtD
Indapamide—Dermatitis—Azathioprine—systemic scleroderma	0.000347	0.000434	CcSEcCtD
Indapamide—Depression—Methotrexate—systemic scleroderma	0.000347	0.000434	CcSEcCtD
Indapamide—Flushing—Prednisone—systemic scleroderma	0.000347	0.000434	CcSEcCtD
Indapamide—Headache—Azathioprine—systemic scleroderma	0.000345	0.000432	CcSEcCtD
Indapamide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000345	0.000432	CcSEcCtD
Indapamide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000345	0.000431	CcSEcCtD
Indapamide—Dizziness—Leflunomide—systemic scleroderma	0.000344	0.00043	CcSEcCtD
Indapamide—Renal failure—Methotrexate—systemic scleroderma	0.000342	0.000428	CcSEcCtD
Indapamide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000341	0.000426	CcSEcCtD
Indapamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00034	0.000425	CcSEcCtD
Indapamide—Stomatitis—Methotrexate—systemic scleroderma	0.000339	0.000424	CcSEcCtD
Indapamide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000338	0.000423	CcSEcCtD
Indapamide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000338	0.000423	CcSEcCtD
Indapamide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000335	0.000419	CcSEcCtD
Indapamide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000335	0.000419	CcSEcCtD
Indapamide—Arrhythmia—Prednisone—systemic scleroderma	0.000334	0.000418	CcSEcCtD
Indapamide—Sweating—Methotrexate—systemic scleroderma	0.000334	0.000417	CcSEcCtD
Indapamide—Vomiting—Leflunomide—systemic scleroderma	0.000331	0.000414	CcSEcCtD
Indapamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000329	0.000412	CcSEcCtD
Indapamide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000329	0.000412	CcSEcCtD
Indapamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000328	0.000411	CcSEcCtD
Indapamide—Rash—Leflunomide—systemic scleroderma	0.000328	0.00041	CcSEcCtD
Indapamide—Dermatitis—Leflunomide—systemic scleroderma	0.000328	0.00041	CcSEcCtD
Indapamide—Nausea—Azathioprine—systemic scleroderma	0.000327	0.000409	CcSEcCtD
Indapamide—Headache—Leflunomide—systemic scleroderma	0.000326	0.000408	CcSEcCtD
Indapamide—Erythema—Prednisone—systemic scleroderma	0.000325	0.000407	CcSEcCtD
Indapamide—Malnutrition—Prednisone—systemic scleroderma	0.000325	0.000407	CcSEcCtD
Indapamide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000325	0.000406	CcSEcCtD
Indapamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000323	0.000404	CcSEcCtD
Indapamide—Asthenia—Lisinopril—systemic scleroderma	0.000321	0.000401	CcSEcCtD
Indapamide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00032	0.000401	CcSEcCtD
Indapamide—Pruritus—Lisinopril—systemic scleroderma	0.000316	0.000396	CcSEcCtD
Indapamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000316	0.000395	CcSEcCtD
Indapamide—Rash—Mycophenolic acid—systemic scleroderma	0.000313	0.000392	CcSEcCtD
Indapamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000313	0.000391	CcSEcCtD
Indapamide—Hepatitis—Methotrexate—systemic scleroderma	0.000312	0.000391	CcSEcCtD
Indapamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000311	0.000389	CcSEcCtD
Indapamide—Headache—Mycophenolic acid—systemic scleroderma	0.000311	0.000389	CcSEcCtD
Indapamide—Pharyngitis—Methotrexate—systemic scleroderma	0.00031	0.000388	CcSEcCtD
Indapamide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00031	0.000387	CcSEcCtD
Indapamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00031	0.000387	CcSEcCtD
Indapamide—Nausea—Leflunomide—systemic scleroderma	0.000309	0.000387	CcSEcCtD
Indapamide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000308	0.000386	CcSEcCtD
Indapamide—Vision blurred—Prednisone—systemic scleroderma	0.000307	0.000384	CcSEcCtD
Indapamide—Urethral disorder—Methotrexate—systemic scleroderma	0.000306	0.000383	CcSEcCtD
Indapamide—Diarrhoea—Lisinopril—systemic scleroderma	0.000306	0.000383	CcSEcCtD
Indapamide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000302	0.000378	CcSEcCtD
Indapamide—Visual impairment—Methotrexate—systemic scleroderma	0.000301	0.000377	CcSEcCtD
Indapamide—Anaemia—Prednisone—systemic scleroderma	0.000301	0.000376	CcSEcCtD
Indapamide—Agitation—Prednisone—systemic scleroderma	0.000299	0.000374	CcSEcCtD
Indapamide—Angioedema—Prednisone—systemic scleroderma	0.000297	0.000372	CcSEcCtD
Indapamide—Dizziness—Lisinopril—systemic scleroderma	0.000296	0.00037	CcSEcCtD
Indapamide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000295	0.000369	CcSEcCtD
Indapamide—Nausea—Mycophenolic acid—systemic scleroderma	0.000295	0.000369	CcSEcCtD
Indapamide—Malaise—Prednisone—systemic scleroderma	0.000293	0.000367	CcSEcCtD
Indapamide—Vertigo—Prednisone—systemic scleroderma	0.000292	0.000366	CcSEcCtD
Indapamide—Syncope—Prednisone—systemic scleroderma	0.000292	0.000365	CcSEcCtD
Indapamide—Tinnitus—Methotrexate—systemic scleroderma	0.000291	0.000364	CcSEcCtD
Indapamide—Cardiac disorder—Methotrexate—systemic scleroderma	0.00029	0.000363	CcSEcCtD
Indapamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000289	0.000361	CcSEcCtD
Indapamide—Loss of consciousness—Prednisone—systemic scleroderma	0.000286	0.000358	CcSEcCtD
Indapamide—Vomiting—Lisinopril—systemic scleroderma	0.000284	0.000356	CcSEcCtD
Indapamide—Rash—Lisinopril—systemic scleroderma	0.000282	0.000353	CcSEcCtD
Indapamide—Dermatitis—Lisinopril—systemic scleroderma	0.000282	0.000352	CcSEcCtD
Indapamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000281	0.000352	CcSEcCtD
Indapamide—Headache—Lisinopril—systemic scleroderma	0.00028	0.00035	CcSEcCtD
Indapamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000347	CcSEcCtD
Indapamide—Myalgia—Prednisone—systemic scleroderma	0.000277	0.000347	CcSEcCtD
Indapamide—Arthralgia—Prednisone—systemic scleroderma	0.000277	0.000347	CcSEcCtD
Indapamide—Anxiety—Prednisone—systemic scleroderma	0.000276	0.000345	CcSEcCtD
Indapamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000275	0.000344	CcSEcCtD
Indapamide—Discomfort—Prednisone—systemic scleroderma	0.000274	0.000342	CcSEcCtD
Indapamide—Erythema—Methotrexate—systemic scleroderma	0.000272	0.00034	CcSEcCtD
Indapamide—Malnutrition—Methotrexate—systemic scleroderma	0.000272	0.00034	CcSEcCtD
Indapamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000268	0.000335	CcSEcCtD
Indapamide—Dysgeusia—Methotrexate—systemic scleroderma	0.000266	0.000333	CcSEcCtD
Indapamide—Nausea—Lisinopril—systemic scleroderma	0.000266	0.000332	CcSEcCtD
Indapamide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000266	0.000332	CcSEcCtD
Indapamide—Oedema—Prednisone—systemic scleroderma	0.000266	0.000332	CcSEcCtD
Indapamide—Infection—Prednisone—systemic scleroderma	0.000264	0.00033	CcSEcCtD
Indapamide—Back pain—Methotrexate—systemic scleroderma	0.000263	0.000329	CcSEcCtD
Indapamide—Shock—Prednisone—systemic scleroderma	0.000261	0.000327	CcSEcCtD
Indapamide—Nervous system disorder—Prednisone—systemic scleroderma	0.00026	0.000326	CcSEcCtD
Indapamide—Tachycardia—Prednisone—systemic scleroderma	0.000259	0.000324	CcSEcCtD
Indapamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000259	0.000324	CcSEcCtD
Indapamide—Skin disorder—Prednisone—systemic scleroderma	0.000258	0.000323	CcSEcCtD
Indapamide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000257	0.000321	CcSEcCtD
Indapamide—Vision blurred—Methotrexate—systemic scleroderma	0.000256	0.000321	CcSEcCtD
Indapamide—Anorexia—Prednisone—systemic scleroderma	0.000253	0.000317	CcSEcCtD
Indapamide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000252	0.000316	CcSEcCtD
Indapamide—Anaemia—Methotrexate—systemic scleroderma	0.000251	0.000314	CcSEcCtD
Indapamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000249	0.000312	CcSEcCtD
Indapamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000247	0.000309	CcSEcCtD
Indapamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000247	0.000309	CcSEcCtD
Indapamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000245	0.000307	CcSEcCtD
Indapamide—Malaise—Methotrexate—systemic scleroderma	0.000245	0.000307	CcSEcCtD
Indapamide—Vertigo—Methotrexate—systemic scleroderma	0.000244	0.000306	CcSEcCtD
Indapamide—Leukopenia—Methotrexate—systemic scleroderma	0.000243	0.000305	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000242	0.000303	CcSEcCtD
Indapamide—Insomnia—Prednisone—systemic scleroderma	0.00024	0.0003	CcSEcCtD
Indapamide—Paraesthesia—Prednisone—systemic scleroderma	0.000238	0.000298	CcSEcCtD
Indapamide—Cough—Methotrexate—systemic scleroderma	0.000237	0.000297	CcSEcCtD
Indapamide—Dyspepsia—Prednisone—systemic scleroderma	0.000234	0.000292	CcSEcCtD
Indapamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000233	0.000291	CcSEcCtD
Indapamide—Chest pain—Methotrexate—systemic scleroderma	0.000231	0.00029	CcSEcCtD
Indapamide—Arthralgia—Methotrexate—systemic scleroderma	0.000231	0.00029	CcSEcCtD
Indapamide—Myalgia—Methotrexate—systemic scleroderma	0.000231	0.00029	CcSEcCtD
Indapamide—Decreased appetite—Prednisone—systemic scleroderma	0.000231	0.000289	CcSEcCtD
Indapamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00023	0.000288	CcSEcCtD
Indapamide—Fatigue—Prednisone—systemic scleroderma	0.000229	0.000286	CcSEcCtD
Indapamide—Discomfort—Methotrexate—systemic scleroderma	0.000229	0.000286	CcSEcCtD
Indapamide—Constipation—Prednisone—systemic scleroderma	0.000227	0.000284	CcSEcCtD
Indapamide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000222	0.000278	CcSEcCtD
Indapamide—Infection—Methotrexate—systemic scleroderma	0.00022	0.000276	CcSEcCtD
Indapamide—Feeling abnormal—Prednisone—systemic scleroderma	0.000219	0.000274	CcSEcCtD
Indapamide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000218	0.000272	CcSEcCtD
Indapamide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000217	0.000272	CcSEcCtD
Indapamide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000217	0.000272	CcSEcCtD
Indapamide—Skin disorder—Methotrexate—systemic scleroderma	0.000216	0.00027	CcSEcCtD
Indapamide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000215	0.000268	CcSEcCtD
Indapamide—Anorexia—Methotrexate—systemic scleroderma	0.000212	0.000265	CcSEcCtD
Indapamide—Urticaria—Prednisone—systemic scleroderma	0.000211	0.000264	CcSEcCtD
Indapamide—Abdominal pain—Prednisone—systemic scleroderma	0.00021	0.000263	CcSEcCtD
Indapamide—Body temperature increased—Prednisone—systemic scleroderma	0.00021	0.000263	CcSEcCtD
Indapamide—Hypotension—Methotrexate—systemic scleroderma	0.000207	0.000259	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000202	0.000253	CcSEcCtD
Indapamide—Insomnia—Methotrexate—systemic scleroderma	0.000201	0.000251	CcSEcCtD
Indapamide—Paraesthesia—Methotrexate—systemic scleroderma	0.000199	0.000249	CcSEcCtD
Indapamide—Dyspnoea—Methotrexate—systemic scleroderma	0.000198	0.000248	CcSEcCtD
Indapamide—Somnolence—Methotrexate—systemic scleroderma	0.000197	0.000247	CcSEcCtD
Indapamide—Hypersensitivity—Prednisone—systemic scleroderma	0.000196	0.000245	CcSEcCtD
Indapamide—Dyspepsia—Methotrexate—systemic scleroderma	0.000195	0.000244	CcSEcCtD
Indapamide—Decreased appetite—Methotrexate—systemic scleroderma	0.000193	0.000241	CcSEcCtD
Indapamide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000192	0.00024	CcSEcCtD
Indapamide—Fatigue—Methotrexate—systemic scleroderma	0.000191	0.000239	CcSEcCtD
Indapamide—Asthenia—Prednisone—systemic scleroderma	0.000191	0.000238	CcSEcCtD
Indapamide—Pain—Methotrexate—systemic scleroderma	0.00019	0.000237	CcSEcCtD
Indapamide—Pruritus—Prednisone—systemic scleroderma	0.000188	0.000235	CcSEcCtD
Indapamide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000183	0.000229	CcSEcCtD
Indapamide—Diarrhoea—Prednisone—systemic scleroderma	0.000182	0.000227	CcSEcCtD
Indapamide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000181	0.000227	CcSEcCtD
Indapamide—Urticaria—Methotrexate—systemic scleroderma	0.000176	0.000221	CcSEcCtD
Indapamide—Dizziness—Prednisone—systemic scleroderma	0.000176	0.00022	CcSEcCtD
Indapamide—Abdominal pain—Methotrexate—systemic scleroderma	0.000175	0.000219	CcSEcCtD
Indapamide—Body temperature increased—Methotrexate—systemic scleroderma	0.000175	0.000219	CcSEcCtD
Indapamide—Vomiting—Prednisone—systemic scleroderma	0.000169	0.000211	CcSEcCtD
Indapamide—Rash—Prednisone—systemic scleroderma	0.000167	0.000209	CcSEcCtD
Indapamide—Dermatitis—Prednisone—systemic scleroderma	0.000167	0.000209	CcSEcCtD
Indapamide—Headache—Prednisone—systemic scleroderma	0.000166	0.000208	CcSEcCtD
Indapamide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000163	0.000205	CcSEcCtD
Indapamide—Asthenia—Methotrexate—systemic scleroderma	0.000159	0.000199	CcSEcCtD
Indapamide—Nausea—Prednisone—systemic scleroderma	0.000158	0.000197	CcSEcCtD
Indapamide—Pruritus—Methotrexate—systemic scleroderma	0.000157	0.000196	CcSEcCtD
Indapamide—Diarrhoea—Methotrexate—systemic scleroderma	0.000152	0.00019	CcSEcCtD
Indapamide—Dizziness—Methotrexate—systemic scleroderma	0.000147	0.000184	CcSEcCtD
Indapamide—Vomiting—Methotrexate—systemic scleroderma	0.000141	0.000177	CcSEcCtD
Indapamide—Rash—Methotrexate—systemic scleroderma	0.00014	0.000175	CcSEcCtD
Indapamide—Dermatitis—Methotrexate—systemic scleroderma	0.00014	0.000175	CcSEcCtD
Indapamide—Headache—Methotrexate—systemic scleroderma	0.000139	0.000174	CcSEcCtD
Indapamide—Nausea—Methotrexate—systemic scleroderma	0.000132	0.000165	CcSEcCtD
